img

Global Primary Immunodeficiency Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Primary Immunodeficiency Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Drugs for the treatment of primary immunodeficiency diseases
Primary Immunodeficiency Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Primary Immunodeficiency Drug market is projected to reach US$ 10690 million in 2029, increasing from US$ 6820 million in 2022, with the CAGR of 6.5% during the period of 2024 to 2029. Demand from Antibody Deficiency and Cellular Immunodeficiency are the major drivers for the industry.
Based on disease or condition, the antibody deficiency segment held the largest share in the overall PIDD market owing to the increasing number of patients diagnosed with common variable immunodeficiency and selective IgA deficiency. In terms of treatment methods, immunoglobulin replacement therapy occupies the largest share of the global PID market, and is an effective, safe and preferred therapy for the treatment of primary immunodeficiency.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Primary Immunodeficiency Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Segment by Type
Immunoglobulin
Antibiotic
Stem Cell
Other

Segment by Application


Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disease
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Primary Immunodeficiency Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Primary Immunodeficiency Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Primary Immunodeficiency Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Primary Immunodeficiency Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Primary Immunodeficiency Drug introduction, etc. Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Primary Immunodeficiency Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Primary Immunodeficiency Drug Market Overview
1.1 Primary Immunodeficiency Drug Product Overview
1.2 Primary Immunodeficiency Drug Market Segment by Type
1.2.1 Immunoglobulin
1.2.2 Antibiotic
1.2.3 Stem Cell
1.2.4 Other
1.3 Global Primary Immunodeficiency Drug Market Size by Type
1.3.1 Global Primary Immunodeficiency Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Primary Immunodeficiency Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Primary Immunodeficiency Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Primary Immunodeficiency Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Primary Immunodeficiency Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Primary Immunodeficiency Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Primary Immunodeficiency Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Primary Immunodeficiency Drug Sales Breakdown by Type (2018-2024)
2 Global Primary Immunodeficiency Drug Market Competition by Company
2.1 Global Top Players by Primary Immunodeficiency Drug Sales (2018-2024)
2.2 Global Top Players by Primary Immunodeficiency Drug Revenue (2018-2024)
2.3 Global Top Players by Primary Immunodeficiency Drug Price (2018-2024)
2.4 Global Top Manufacturers Primary Immunodeficiency Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Primary Immunodeficiency Drug Market Competitive Situation and Trends
2.5.1 Primary Immunodeficiency Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Primary Immunodeficiency Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Immunodeficiency Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Primary Immunodeficiency Drug Market
2.8 Key Manufacturers Primary Immunodeficiency Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Primary Immunodeficiency Drug Status and Outlook by Region
3.1 Global Primary Immunodeficiency Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Primary Immunodeficiency Drug Historic Market Size by Region
3.2.1 Global Primary Immunodeficiency Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Primary Immunodeficiency Drug Sales in Value by Region (2018-2024)
3.2.3 Global Primary Immunodeficiency Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Primary Immunodeficiency Drug Forecasted Market Size by Region
3.3.1 Global Primary Immunodeficiency Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Primary Immunodeficiency Drug Sales in Value by Region (2024-2029)
3.3.3 Global Primary Immunodeficiency Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Primary Immunodeficiency Drug by Application
4.1 Primary Immunodeficiency Drug Market Segment by Application
4.1.1 Antibody Deficiency
4.1.2 Cellular Immunodeficiency
4.1.3 Innate Immune Disease
4.1.4 Other
4.2 Global Primary Immunodeficiency Drug Market Size by Application
4.2.1 Global Primary Immunodeficiency Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Primary Immunodeficiency Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Primary Immunodeficiency Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Primary Immunodeficiency Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Primary Immunodeficiency Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Primary Immunodeficiency Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Primary Immunodeficiency Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Primary Immunodeficiency Drug Sales Breakdown by Application (2018-2024)
5 North America Primary Immunodeficiency Drug by Country
5.1 North America Primary Immunodeficiency Drug Historic Market Size by Country
5.1.1 North America Primary Immunodeficiency Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Primary Immunodeficiency Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Primary Immunodeficiency Drug Sales in Value by Country (2018-2024)
5.2 North America Primary Immunodeficiency Drug Forecasted Market Size by Country
5.2.1 North America Primary Immunodeficiency Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Primary Immunodeficiency Drug Sales in Value by Country (2024-2029)
6 Europe Primary Immunodeficiency Drug by Country
6.1 Europe Primary Immunodeficiency Drug Historic Market Size by Country
6.1.1 Europe Primary Immunodeficiency Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Primary Immunodeficiency Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Primary Immunodeficiency Drug Sales in Value by Country (2018-2024)
6.2 Europe Primary Immunodeficiency Drug Forecasted Market Size by Country
6.2.1 Europe Primary Immunodeficiency Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Primary Immunodeficiency Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Primary Immunodeficiency Drug by Region
7.1 Asia-Pacific Primary Immunodeficiency Drug Historic Market Size by Region
7.1.1 Asia-Pacific Primary Immunodeficiency Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Primary Immunodeficiency Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Primary Immunodeficiency Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Primary Immunodeficiency Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Primary Immunodeficiency Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Primary Immunodeficiency Drug Sales in Value by Region (2024-2029)
8 Latin America Primary Immunodeficiency Drug by Country
8.1 Latin America Primary Immunodeficiency Drug Historic Market Size by Country
8.1.1 Latin America Primary Immunodeficiency Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Primary Immunodeficiency Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Primary Immunodeficiency Drug Sales in Value by Country (2018-2024)
8.2 Latin America Primary Immunodeficiency Drug Forecasted Market Size by Country
8.2.1 Latin America Primary Immunodeficiency Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Primary Immunodeficiency Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Primary Immunodeficiency Drug by Country
9.1 Middle East and Africa Primary Immunodeficiency Drug Historic Market Size by Country
9.1.1 Middle East and Africa Primary Immunodeficiency Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Primary Immunodeficiency Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Primary Immunodeficiency Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Primary Immunodeficiency Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Primary Immunodeficiency Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Primary Immunodeficiency Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 ADMA Biologics, Inc.
10.1.1 ADMA Biologics, Inc. Company Information
10.1.2 ADMA Biologics, Inc. Introduction and Business Overview
10.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drug Products Offered
10.1.5 ADMA Biologics, Inc. Recent Development
10.2 CSL Behring, LLC
10.2.1 CSL Behring, LLC Company Information
10.2.2 CSL Behring, LLC Introduction and Business Overview
10.2.3 CSL Behring, LLC Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 CSL Behring, LLC Primary Immunodeficiency Drug Products Offered
10.2.5 CSL Behring, LLC Recent Development
10.3 Octapharma
10.3.1 Octapharma Company Information
10.3.2 Octapharma Introduction and Business Overview
10.3.3 Octapharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Octapharma Primary Immunodeficiency Drug Products Offered
10.3.5 Octapharma Recent Development
10.4 Takeda Pharmaceutical Company
10.4.1 Takeda Pharmaceutical Company Company Information
10.4.2 Takeda Pharmaceutical Company Introduction and Business Overview
10.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Products Offered
10.4.5 Takeda Pharmaceutical Company Recent Development
10.5 Grifols Biologicals, Inc.
10.5.1 Grifols Biologicals, Inc. Company Information
10.5.2 Grifols Biologicals, Inc. Introduction and Business Overview
10.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Products Offered
10.5.5 Grifols Biologicals, Inc. Recent Development
10.6 Baxter
10.6.1 Baxter Company Information
10.6.2 Baxter Introduction and Business Overview
10.6.3 Baxter Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Baxter Primary Immunodeficiency Drug Products Offered
10.6.5 Baxter Recent Development
10.7 Kedrion Biopharma
10.7.1 Kedrion Biopharma Company Information
10.7.2 Kedrion Biopharma Introduction and Business Overview
10.7.3 Kedrion Biopharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Kedrion Biopharma Primary Immunodeficiency Drug Products Offered
10.7.5 Kedrion Biopharma Recent Development
10.8 BPL Inc.
10.8.1 BPL Inc. Company Information
10.8.2 BPL Inc. Introduction and Business Overview
10.8.3 BPL Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 BPL Inc. Primary Immunodeficiency Drug Products Offered
10.8.5 BPL Inc. Recent Development
10.9 Pharming Group
10.9.1 Pharming Group Company Information
10.9.2 Pharming Group Introduction and Business Overview
10.9.3 Pharming Group Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Pharming Group Primary Immunodeficiency Drug Products Offered
10.9.5 Pharming Group Recent Development
10.10 Shire
10.10.1 Shire Company Information
10.10.2 Shire Introduction and Business Overview
10.10.3 Shire Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Shire Primary Immunodeficiency Drug Products Offered
10.10.5 Shire Recent Development
10.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
10.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Company Information
10.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Introduction and Business Overview
10.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Products Offered
10.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Primary Immunodeficiency Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Primary Immunodeficiency Drug Industrial Chain Analysis
11.4 Primary Immunodeficiency Drug Market Dynamics
11.4.1 Primary Immunodeficiency Drug Industry Trends
11.4.2 Primary Immunodeficiency Drug Market Drivers
11.4.3 Primary Immunodeficiency Drug Market Challenges
11.4.4 Primary Immunodeficiency Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Primary Immunodeficiency Drug Distributors
12.3 Primary Immunodeficiency Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Immunoglobulin
Table 2. Major Company of Antibiotic
Table 3. Major Company of Stem Cell
Table 4. Major Company of Other
Table 5. Global Primary Immunodeficiency Drug Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Primary Immunodeficiency Drug Sales by Type (2018-2024) & (K Units)
Table 7. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US& Million)
Table 9. Global Primary Immunodeficiency Drug Market Share in Value by Type (2018-2024)
Table 10. Global Primary Immunodeficiency Drug Price by Type (2018-2024) & (US$/Unit)
Table 11. Global Primary Immunodeficiency Drug Sales by Type (2024-2029) & (K Units)
Table 12. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Primary Immunodeficiency Drug Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Primary Immunodeficiency Drug Sales Market Share in Value by Type (2024-2029)
Table 15. Global Primary Immunodeficiency Drug Price by Type (2024-2029) & (US$/Unit)
Table 16. North America Primary Immunodeficiency Drug Sales by Type (2018-2024) & (K Units)
Table 17. North America Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Primary Immunodeficiency Drug Sales (K Units) by Type (2018-2024)
Table 19. Europe Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Primary Immunodeficiency Drug Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Primary Immunodeficiency Drug Sales (K Units) by Type (2018-2024)
Table 23. Latin America Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Primary Immunodeficiency Drug Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Primary Immunodeficiency Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Primary Immunodeficiency Drug Sales by Company (2018-2024) & (K Units)
Table 27. Global Primary Immunodeficiency Drug Sales Share by Company (2018-2024)
Table 28. Global Primary Immunodeficiency Drug Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Primary Immunodeficiency Drug Revenue Share by Company (2018-2024)
Table 30. Global Market Primary Immunodeficiency Drug Price by Company (2018-2024) & (US$/Unit)
Table 31. Global Primary Immunodeficiency Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Primary Immunodeficiency Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Immunodeficiency Drug as of 2022)
Table 34. Date of Key Manufacturers Enter into Primary Immunodeficiency Drug Market
Table 35. Key Manufacturers Primary Immunodeficiency Drug Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Primary Immunodeficiency Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Primary Immunodeficiency Drug Sales by Region (2018-2024) & (K Units)
Table 39. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Primary Immunodeficiency Drug Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Primary Immunodeficiency Drug Sales Market Share in Value by Region (2018-2024)
Table 42. Global Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 43. Global Primary Immunodeficiency Drug Sales by Region (2024-2029) & (K Units)
Table 44. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Primary Immunodeficiency Drug Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Primary Immunodeficiency Drug Sales Market Share in Value by Region (2024-2029)
Table 47. Global Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 48. Global Primary Immunodeficiency Drug Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Primary Immunodeficiency Drug Sales by Application (2018-2024) & (K Units)
Table 50. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Primary Immunodeficiency Drug Sales Market Share in Value by Application (2018-2024)
Table 53. Global Primary Immunodeficiency Drug Price by Application (2018-2024) & (US$/Unit)
Table 54. Global Primary Immunodeficiency Drug Sales by Application (2024-2029) & (K Units)
Table 55. Global Primary Immunodeficiency Drug Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Primary Immunodeficiency Drug Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Primary Immunodeficiency Drug Sales Market Share in Value by Application (2024-2029)
Table 58. Global Primary Immunodeficiency Drug Price by Application (2024-2029) & (US$/Unit)
Table 59. North America Primary Immunodeficiency Drug Sales by Application (2018-2024) (K Units)
Table 60. North America Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Primary Immunodeficiency Drug Sales by Application (2018-2024) (K Units)
Table 62. Europe Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Primary Immunodeficiency Drug Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Primary Immunodeficiency Drug Sales by Application (2018-2024) (K Units)
Table 66. Latin America Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Primary Immunodeficiency Drug Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Primary Immunodeficiency Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 70. North America Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Primary Immunodeficiency Drug Sales Market Share in Value by Country (2018-2024)
Table 73. North America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 74. North America Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Primary Immunodeficiency Drug Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 78. Europe Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Primary Immunodeficiency Drug Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Primary Immunodeficiency Drug Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 82. Europe Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Primary Immunodeficiency Drug Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Primary Immunodeficiency Drug Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Primary Immunodeficiency Drug Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Primary Immunodeficiency Drug Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Primary Immunodeficiency Drug Sales by Region (2024-2029) & (K Units)
Table 90. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Primary Immunodeficiency Drug Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Primary Immunodeficiency Drug Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 98. Latin America Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Primary Immunodeficiency Drug Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 106. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Value by Country (2024-2029)
Table 109. ADMA Biologics, Inc. Company Information
Table 110. ADMA Biologics, Inc. Introduction and Business Overview
Table 111. ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. ADMA Biologics, Inc. Primary Immunodeficiency Drug Product
Table 113. ADMA Biologics, Inc. Recent Development
Table 114. CSL Behring, LLC Company Information
Table 115. CSL Behring, LLC Introduction and Business Overview
Table 116. CSL Behring, LLC Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. CSL Behring, LLC Primary Immunodeficiency Drug Product
Table 118. CSL Behring, LLC Recent Development
Table 119. Octapharma Company Information
Table 120. Octapharma Introduction and Business Overview
Table 121. Octapharma Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Octapharma Primary Immunodeficiency Drug Product
Table 123. Octapharma Recent Development
Table 124. Takeda Pharmaceutical Company Company Information
Table 125. Takeda Pharmaceutical Company Introduction and Business Overview
Table 126. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product
Table 128. Takeda Pharmaceutical Company Recent Development
Table 129. Grifols Biologicals, Inc. Company Information
Table 130. Grifols Biologicals, Inc. Introduction and Business Overview
Table 131. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product
Table 133. Grifols Biologicals, Inc. Recent Development
Table 134. Baxter Company Information
Table 135. Baxter Introduction and Business Overview
Table 136. Baxter Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Baxter Primary Immunodeficiency Drug Product
Table 138. Baxter Recent Development
Table 139. Kedrion Biopharma Company Information
Table 140. Kedrion Biopharma Introduction and Business Overview
Table 141. Kedrion Biopharma Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Kedrion Biopharma Primary Immunodeficiency Drug Product
Table 143. Kedrion Biopharma Recent Development
Table 144. BPL Inc. Company Information
Table 145. BPL Inc. Introduction and Business Overview
Table 146. BPL Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. BPL Inc. Primary Immunodeficiency Drug Product
Table 148. BPL Inc. Recent Development
Table 149. Pharming Group Company Information
Table 150. Pharming Group Introduction and Business Overview
Table 151. Pharming Group Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Pharming Group Primary Immunodeficiency Drug Product
Table 153. Pharming Group Recent Development
Table 154. Shire Company Information
Table 155. Shire Introduction and Business Overview
Table 156. Shire Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Shire Primary Immunodeficiency Drug Product
Table 158. Shire Recent Development
Table 159. Chengdu Rongsheng Pharmaceutical Co., Ltd Company Information
Table 160. Chengdu Rongsheng Pharmaceutical Co., Ltd Introduction and Business Overview
Table 161. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product
Table 163. Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Development
Table 164. Key Raw Materials Lists
Table 165. Raw Materials Key Suppliers Lists
Table 166. Primary Immunodeficiency Drug Market Trends
Table 167. Primary Immunodeficiency Drug Market Drivers
Table 168. Primary Immunodeficiency Drug Market Challenges
Table 169. Primary Immunodeficiency Drug Market Restraints
Table 170. Primary Immunodeficiency Drug Distributors List
Table 171. Primary Immunodeficiency Drug Downstream Customers
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Immunodeficiency Drug Product Picture
Figure 2. Global Primary Immunodeficiency Drug Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Primary Immunodeficiency Drug Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Primary Immunodeficiency Drug Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Immunoglobulin
Figure 6. Global Immunoglobulin Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Antibiotic
Figure 8. Global Antibiotic Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Stem Cell
Figure 10. Global Stem Cell Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Other
Figure 12. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Global Primary Immunodeficiency Drug Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Primary Immunodeficiency Drug Sales Market Share by Type in 2022 & 2029
Figure 15. North America Primary Immunodeficiency Drug Sales Market Share in Volume by Type in 2022
Figure 16. North America Primary Immunodeficiency Drug Sales Market Share in Value by Type in 2022
Figure 17. Europe Primary Immunodeficiency Drug Sales Market Share in Volume by Type in 2022
Figure 18. Europe Primary Immunodeficiency Drug Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Value by Type in 2022
Figure 21. Latin America Primary Immunodeficiency Drug Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Primary Immunodeficiency Drug Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Primary Immunodeficiency Drug Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Primary Immunodeficiency Drug Revenue in 2022
Figure 27. Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Antibody Deficiency
Figure 29. Global Antibody Deficiency Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Cellular Immunodeficiency
Figure 31. Global Cellular Immunodeficiency Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Innate Immune Disease
Figure 33. Global Innate Immune Disease Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Product Picture of Other
Figure 35. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 36. Global Primary Immunodeficiency Drug Sales by Application (2018-2029) & (US$ Million)
Figure 37. Global Primary Immunodeficiency Drug Sales Market Share by Application in 2022 & 2029
Figure 38. North America Primary Immunodeficiency Drug Sales Market Share in Volume by Application in 2022
Figure 39. North America Primary Immunodeficiency Drug Sales Market Share in Value by Application in 2022
Figure 40. Europe Primary Immunodeficiency Drug Sales Market Share in Volume by Application in 2022
Figure 41. Europe Primary Immunodeficiency Drug Sales Market Share in Value by Application in 2022
Figure 42. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Volume by Application in 2022
Figure 43. Asia-Pacific Primary Immunodeficiency Drug Sales Market Share in Value by Application in 2022
Figure 44. Latin America Primary Immunodeficiency Drug Sales Market Share in Volume by Application in 2022
Figure 45. Latin America Primary Immunodeficiency Drug Sales Market Share in Value by Application in 2022
Figure 46. Middle East and Africa Primary Immunodeficiency Drug Sales Market Share in Value by Application in 2022
Figure 47. Key Raw Materials Price
Figure 48. Primary Immunodeficiency Drug Manufacturing Cost Structure
Figure 49. Primary Immunodeficiency Drug Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries